In the U.S., sinusitis is more prevalent than arthritis and hypertension and, when chronic, can be as debilitating as diabetes and cardiovascular disease. Unfortunately, lack of a clear definition of chronic rhinosinusitis (CRS) has made it difficult for clinicians to provide effective care or develop new drug therapies. The Sinus and Allergy Health Partnership (SAHP) recently published guidelines that enumerate the multiple causes of and appropriate diagnosis criteria for CRS that may lead to improved therapies for the condition. The guidelines were published in a recent issue of Otolaryngology-Head and Neck Surgery.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.